NoS
I for one will continue to value your thoughts…..as a long term follower of HCM I expect you will keep an eye on it, in case there is a change of tone and fortune - I also expect you will buy back in at some point…
Good luck with your new investments….tell us what you select. |
Bareknee - Bitter posts just make it look like you're continually trying to validate your reasons for selling.
Not at all, I was stating the facts as I see them.. |
Let it go DaveyNerd. For better or worse you've sold up.
Bitter posts just make it look like you're continually trying to validate your reasons for selling. It's like the reverse of the Quindell situation was for you.
Live, learn and move on, but don't give up the day job ! |
Agree Lauders; to not engage with shareholders and do absolutely nothing given the recent decline, does just smack of apathy, and comes across as a little feeble. |
It has been stated they don't really "care" about their shareholders mcmather. I suppose your point sort of confirms this, unfortunately. |
Shame there wasn't an update of sorts:
"HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT)." |
Bleak viewing the decline over the last 12 months |
and the share price falls again as usual |
Bit more coverage just landed (nothing really more) here:
“Hutchmed celebrates cancer drug approval in hometown of Hong Kong”
And a bit of coverage from last week (23 Jan 2024): “Patients with previously treated metastatic colorectal cancer (CRC) experienced significant improvement in quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) when treated with a combination of Fruzaqla (fruquintinib) with best supportive care when compared with treatment via placebo and best supportive care, according to post hoc analysis findings from the phase 3 FRESCO-2 trial presented at the 2024 Gastrointestinal Cancers Symposium.” |
Closed down 0.25% so the news managed to claw back some of the earlier losses. |
Some good news from HCM today.
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 30, 2024: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMEDR21;) today announces that the marketing approval of ELUNATE® (fruquintinib) by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). ELUNATE® is a selective oral inhibitor of vascular endothelial growth factor (“VEGF”) receptors -1, -2 and -3, which play a pivotal role in blocking tumor angiogenesis.
Will it be enough to make the share price + for once? Currently DOWN in HK by 1.88%! |
"But hcm still irritates you"
not really, I was just posting an observation about geo-politics at play here and yes I have sold, but I may well buy back in if things begin to improve. In the meantime I've made a packet on Nvidia, more in a month than I have being invested in HCM over 7 years... |
Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.
I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos.
It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years….
I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy. |
One thing is for sure. Anyone with funds to invest at these low RSI levels will make some money going forward. Can't stay at these levels forever, surely? Just needs some good news on trials, M&A activity, sales and a rebound should materialize. Down over 20% this year alone! |
NoS I thought you were out? Really this time. But hcm still irritates you. Why? Move on. |
just think, HK investors who took shares at the IPO have lost two thirds of their money
China is now effectively uninvestible and the Chinese Communist Party knows it. The property sector is collapsing and everything else will follow. |
The Company seems to be quite inept when it comes to Investors, particularly individual ones. I have asked many important questions at the AGM and Simon To has always treated me with disdain. They also need to update their pipeline, it's 6 months out of date. |
Agree, it does make a difference especially if read out at a board meeting, could just be enough to sway opinion.
Posted a few more ideas on other board if you have access.
Lauders22 Jan '24 - 08:58 - 3988 of 3991 |
US closed -7.50%. Will we see any response from the company?
There appeared to be support on the US weekly at 14.48ish. Hmmmm.
FWIW: "The 55 rating InvestorsObserver gives to HUTCHMED (China) Ltd (HCM) stock puts it near the top of the Drug Manufacturers - Specialty & Generic industry. In addition to scoring higher than 80 percent of stocks in the Drug Manufacturers - Specialty & Generic industry, HCM’s 55 overall rating means the stock scores better than 55 percent of all stocks...Over the past year the S&P 500 has risen 20.68% while HCM has fallen -26.98%" |
Good point. What is to stop the majority shareholder making a cheap bid for the remaining shares, although it would need to get > 75%. |
At this rate Hutchison will buy it back themselves .
It would be a great deal for them! |
I know there's not many on his board, but could I suggest copying above link along with a note and sending into the board for airing - if anyone needs contact details I can post here.
Already sent an e-mail with the suggestion to ir@hutch-med.com
Not sure it will do any good but if we don't try we will never know. The price is really being hit at present. Why though? I suppose, yet again, it is a chance to top-up near 200p, but why do so when the IR/PR is so poor and the share price continues to depress? |
Guess yesterday's presentation didn't go down that well...
The company certainly need to do something; the market is presently saying that they aren't very smart.
(US) 14.04 quote price -8.12% |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
